Best Peptides for Fat Loss Research in Australia 2026
Fat loss is the most active area of peptide research in 2026, driven by the GLP-1 receptor agonist class. This guide compares the compounds researchers in Australia are actually studying, by receptor target and research context, not by hype.
Retatrutide, the triple-agonist benchmark
Retatrutide is the most discussed metabolic peptide in current research. It is a triple agonist, targeting GLP-1, GIP, and glucagon receptor pathways simultaneously. The glucagon receptor is the distinguishing feature, it adds an energy-expenditure and lipid-handling dimension that dual agonists do not address.
For researchers studying fat loss, appetite suppression, and metabolic signalling, retatrutide is the benchmark compound. It is available in 10mg and 20mg vials from Polaris Research with independently verified batch certificates and Free Express Delivery Australia-wide.
The GLP-1 / GIP / glucagon distinction
The metabolic peptide class is defined by which receptors a compound reaches. GLP-1 receptors reduce appetite and slow gastric emptying. GIP receptors enhance insulin sensitivity and may amplify fat loss. Glucagon receptors increase energy expenditure by stimulating the liver to burn more fuel. The combination of all three is what makes retatrutide the most studied compound in the class.
Earlier compounds reach fewer receptors. Semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) are the predecessors, and both are still widely studied. The progression from single to dual to triple agonism is the research trajectory that defines this family. For a detailed head-to-head, see our Retatrutide vs Tirzepatide guide.
Other compounds in the metabolic family
Beyond retatrutide, the metabolic family includes tesamorelin (a GHRH analogue studied for metabolic and growth-hormone signalling), MOTS-c (a mitochondrial-derived peptide studied for AMPK and glucose metabolism), and AOD-9604 (a fragment peptide studied for lipid metabolism). Each targets a different side of the metabolic picture, appetite, energy expenditure, or lipid handling.
The most experienced researchers often start with retatrutide as the benchmark compound and then explore the others as complementary research questions. As always, one compound at a time is the right starting point, so you can actually tell what is doing what.
The foundations come first
No metabolic peptide outperforms poor food, poor sleep, and no movement. The research literature is explicit on this point: signalling compounds are studied alongside the foundations, not instead of them. The people who get the most from this family are the ones who already have the basics steady and are looking to understand the next layer.
Every metabolic peptide from Polaris Research ships with an independently verified batch certificate (≥98% purity) and free Australia Post Express Delivery Australia-wide. For a complete walkthrough of the range, see our Considered Catalogue guide.
Every order ships free Express Australia-wide, with tracking and support when you need it.
Educational information only. Nothing here is medical advice or a therapeutic claim. Speak with a qualified healthcare professional before beginning any protocol. Last reviewed 23 June 2026.
Independent reading
Our library is introductory research-supply context. When you want published-evidence summaries written for researchers, reptides.co is a useful next step. It is entirely separate from this store.
- Peptide tier list47 peptides ranked S–F by published human evidence — free to browse from the reptides homepage.reptides.co
- MethodologyHow tiers are set, how citations are audited, and how rankings change when trial data moves.reptides.co
- Weight lossEditorial guide to GLP-1 class peptides and related metabolic compounds.reptides.co
- Recovery & injuryHealing-category peptides — what the preclinical and clinical record actually shows.reptides.co
- Skin & anti-agingCopper peptides, blends, and cosmetic-category evidence in one place.reptides.co
- Growth hormone axisSecretagogues, GHRH analogs, and how the evidence stacks up.reptides.co
- Focus & cognitionNootropic peptides — trial history, mechanisms, and where the record is thin.reptides.co
- LongevityMitochondrial peptides, bioregulators, and what is still preclinical.reptides.co
- Peptide market mapSupply chain, testing, pricing context, and regulatory movement — updated quarterly.reptides.co
Independent third-party research on reptides.co — not affiliated with Polaris Research. Research reference only, not medical advice.